Vol 20, No 2 (2024)
Research paper
Published online: 2023-11-06

open access

Page views 220
Article views/downloads 138
Get Citation

Connect on Social Media

Connect on Social Media

The effect of different concentrations of anti-PD-1 and anti-PD-L1 antibodies on the activity of immune system cells in patients with non-small cell lung cancer

Aleksandra Bożyk1, Kamila Wojas-Krawczyk1, Marcin Nicoś1, Paweł Krawczyk1
Oncol Clin Pract 2024;20(2):124-135.

Abstract

Introduction. The last century abounded in numerous scientific discoveries that allowed us to understand the operation and functioning of one of the most complex human systems, i.e. the immune system. One of the most important discoveries was the work of Prof. James Alison and Prof. Tasuko Honjo on the development of anti-cancer therapy inhibiting negative immune regulation (PD-1 and CTLA-4 molecules). Knowledge of these molecules’ action and their huge role in inhibiting immune system activity, e.g. during cancer growth, created the basis for the development of specific monoclonal antibodies, without which clinicians from many specialties cannot imagine modern cancer therapies. However, side effects of these therapies are still quite troublesome.To minimize them, it would be necessary to reduce the dose while still maintaining the effective level of anticancer activity of immune system cells. 

Material and methods. In this study, 24-hour culture of PBMCs isolated from blood and bronchoaspirate with various concentrations of nivolumab or atezolizumab was performed. Expression of the individual activation markers on cultured cells was compared to the expression of these markers on cells not subjected to cell culture. 

Results and conclusions. The outcomes of our research may indicate that individualized dosages of anti-PD-1 and anti-PD-L1 antibodies may contribute to the effective activation of immune system cells while minimizing the side effects of the therapy.

Article available in PDF format

View PDF Download PDF file

References

  1. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012; 24(2): 207–212.
  2. Wojas-Krawczyk K. Podstawy immunoonkologii, cz. 1. Conference "Nowości w leczeniu nowotworów klatki piersiowej", Warszawa 2016.
  3. Alonso-García M, Sánchez-Gastaldo A, Muñoz-Fuentes MA, et al. Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Pharmaceuticals (Basel). 2022; 15(5).
  4. Gołąb J, Jakóbisiak M, Lasek W, Stokłosa T. Immunologia. PWN 2017.
  5. Kayser G, Schulte-Uentrop L, Sienel W, et al. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas. Lung Cancer. 2012; 76(3): 445–451.
  6. Mita Y, Kimura M, Hayashizaki K, et al. Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells. International Immunology. 2018; 30(12): 559–567.
  7. Risso V, Lafont E, Gallo MLe. Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases. Cell Death & Disease. 2022; 13(3).
  8. Wang Q, Xie B, Liu S, et al. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol. 2021; 12: 773168.
  9. Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5): 275–287.
  10. Yost KE, Satpathy AT, Wells DK, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019; 25(8): 1251–1259.
  11. Jin Y, Shen X, Pan Y, et al. Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. J Thorac Dis. 2019; 11(11): 4591–4601.
  12. Gros A, Parkhurst MR, Tran E, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4): 433–438.
  13. Kim KH, Kim CG, Shin EC. Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. Immune Netw. 2020; 20(1): e8.
  14. Duan Q, Zhang H, Zheng J, et al. Turning Cold into Hot: Firing up the Tumor Microenvironment. Trends Cancer. 2020; 6(7): 605–618.
  15. Bonaventura P, Shekarian T, Alcazer V, et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol. 2019; 10: 168.